Cost Watchdog Opens Review of Psilocybin Ahead of FDA Filing

The Institute for Clinical and Economic Review opened an assessment Wednesday of synthetic psilocybin for treatment-resistant depression, a review that will weigh what the drug does against what it costs before federal regulators finish evaluating it. Public comment on ICER's draft scoping document runs through Nov. 10, and a New England CEPAC public meeting is scheduled for May 20, 2027.

The intervention under review is COMP360, the proprietary psilocybin formulation developed by Compass Pathways. It is the furthest along of the psychedelic programs now moving through the U.S. regulatory system, and the one most likely to be first to market.

What ICER does, and why insurers watch it

ICER is an independent nonprofit that produces health technology assessments — long reports that compare a new treatment with existing options, estimate its budget impact and, in many cases, calculate a price range consistent with its measured benefit. Its reports do not bind anyone. But they are read closely by pharmacy benefit managers, state Medicaid programs and commercial insurers, and they have a track record of shaping how quickly and at what price a new therapy gets covered.

The organization has already been through this once with a psychedelic. In 2024 it published a review of midomafetamine-assisted psychotherapy for post-traumatic stress disorder, completing the assessment while that program was still in front of the FDA.

For this review, ICER's scoping notice lists the organizations it has asked for input: Compass Pathways, Definium Therapeutics, the Depression and Bipolar Support Alliance, Letters to Strangers, Mental Health America and NAMI.

Where the drug stands with regulators

COMP360 rests on two late-stage trials in treatment-resistant depression, a condition defined by failure to respond to at least two adequate courses of antidepressant treatment. Compass reported in February that the second of those Phase 3 trials met its primary endpoint, and in July released 26-week follow-up data describing a durable response.

The FDA granted the company's request for a rolling new drug application, which lets Compass submit sections of its filing for review as they are completed, and selected COMP360 for the Commissioner's National Priority Voucher program in April. Compass has said it expects to finish the rolling submission in the fourth quarter of 2026.

That timetable is why the sequencing here is unusual. Priority-voucher reviews are designed to move in weeks rather than the standard ten to twelve months. If the submission closes this quarter and the review runs on that compressed schedule, a federal decision could arrive well before ICER's May 2027 meeting — leaving payers to write coverage policy on a drug that ICER has not yet scored.

What the assessment will weigh

ICER reviews are built around comparisons. The draft scoping document sets out which patient populations and which existing treatments the review will use as benchmarks, and that document is what the public can comment on until Nov. 10.

The economics are not incidental for this class of treatment. Psilocybin therapy is not a bottle of pills taken at home. In the trials, COMP360 was administered in supervised sessions with trained facilitators present, and patients were monitored for hours afterward. Whatever the acquisition price of the drug turns out to be, the delivery model carries its own costs, and those costs fall on the clinics, health systems and insurers that would have to build the infrastructure.

The mental health stakes are also specific. Treatment-resistant depression is the label given to patients who have already cycled through multiple medications, a group with high rates of disability and suicide risk, and one that has had few new options in decades. Whether a six-hour supervised session with a psychedelic compound, plus ongoing outpatient care, looks like value for money is exactly the question ICER exists to answer.

For context on how the regulatory path got here — the April executive order directing agencies to accelerate psychedelic review, and the voucher mechanism that followed — our earlier reporting on psilocybin's approach to FDA approval lays out the timeline.

What the review does not decide

Nothing in ICER's process changes the FDA's judgment about safety and efficacy, and an ICER report is not a coverage mandate. A payer that dislikes the conclusion can ignore it; a payer that likes it can cite it.

The assessment is also narrower than the public debate about psychedelics. It covers synthetic psilocybin for treatment-resistant depression, not psilocybin generally, not other compounds, and not the state-licensed service center model that has developed in Oregon and Colorado. The scope is a single drug, in a single indication, compared against a defined set of alternatives.

What it can do is put a number on the therapy's value before the market does — and give insurers, clinicians and patients a shared document to argue about. That argument opens with the comment period, and it will not close until the votes are tallied in New England next spring.